OPT
Delivery · High$18M64mo
Opthea
Biotech · Ophthalmology
Sozinibercept for wet AMD, partnered with Carlyle
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$31.2M
Mar 2026 4C
Runway
64moSTABLE
Based on Mar 2026 4C
Market Cap
$18M
Burn Rate
$1.5M/qtr
Mar 2026 4C
Shares Outstanding
1.4B
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther2 June 2026
Reinstatement to ASX and Update on LAM Development Program
Opthea announces reinstatement to ASX trading following strategic review to focus on OPT-302 development for lymphangioleiomyomatosis (LAM), a rare pulmonary disease with unmet medical need. The company has an 18-month staged development program funded by existing cash reserves of A$31.2 million, with estimated expenditure of A$13.1 million over the program period. The company is also undertaking a name change to Ceryvyn Therapeutics Limited to reflect its strategic refocus.
3M Price
OPT.ASX$0.013-97.8% 3M
Low $0.013High $0.600
Pipeline Assets (2)
SoziniberceptDME
Phase 2SoziniberceptDiscontinued
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
4 transactionsLast 90dNo Activity
Buys0
Sells0
OPTIONS EXERCISEKatherine Connellopen_in_new
02025-12-19
110d before · Results posted — OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Catalysts (11)· 2 upcoming · 9 past
Sozinibercept Phase 3 wet AMD topline
UpcomingExpectedarrow_upwardHigh30 June 2026
Expectedarrow_upwardHigh2 Dec 2027
expand_more9 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High75/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High74/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 3 of 3 guided dates· rolling 2yr· of 11 tracked
Filed 2 of 2 4Cs on time· statutory deadline· 6 filings without matched announcement
What drove these scores · rolling 2yr
arrow_drop_down
Volatile burn rate — 44% quarterly variation — inconsistent spend
arrow_drop_down
Cash position declining — Cash balance dropped >30% over last 3 quarters
arrow_drop_up
Capital raise required — Delivered 304d early
arrow_drop_up
Burn reductions achieved — 2 quarters with >30% spend reduction
arrow_drop_up
R&D-focused spend — 89% of opex directed to R&D
·
Reinstatement to Official Quotation — Delivered on time
·
Reinstatement to ASX and Update on LAM Development Program — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (3/6 data points) — accuracy improves with more completed catalysts
·
Mixed cash flow — Burn volatility calculated from 7 burning quarters only
Completed catalysts
✓Capital raise required— Cash position improved from $28M to $86M in Q2 2025 (raise completed). Company CF positive by Q4 2025.
304d early
✓Reinstatement to Official Quotation
On time
✓Reinstatement to ASX and Update on LAM Development Program— Opthea announces reinstatement to ASX trading following strategic review to focus on OPT-302 development for lymphangioleiomyomatosis (LAM), a rare pulmonary disease with unmet medical need. The company has an 18-month staged development program funded by existing cash reserves of A$31.2 million, with estimated expenditure of A$13.1 million over the program period. The company is also undertaking a name change to Ceryvyn Therapeutics Limited to reflect its strategic refocus.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
No active trials
Announcements(12)
article
OtherPSauto_awesome
Reinstatement to ASX and Update on LAM Development Program2 June 2026
expand_more249KB